Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab added to DHAP/VIM before autologous stem cell transplantation in relapsed B-cell non-Hodgkin lymphoma
NL-OMON29096Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Nov 2000
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in non-Hodgkin lymphoma (NHL) and mature B-cell lymphoma (2 arms), sponsored by HOVON. Primary endpoint: Overall survival. Started Nov 2000; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON29096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29096.